Synthesis of LSD-25 at Sandoz

The synthesis of LSD-25 at Sandoz gave researchers a new compound whose significance emerged through an unusual combination of chemical discovery and open-ended distribution. Albert Hofmann’s first LSD experience in 1943 came without prior expectations; although he could not tell whether he had encountered madness or transcendence, he immediately recognized the compound’s possible importance for neurology and psychiatry. Sandoz then made LSD available without charge to a broad range of investigators, helping turn an experimental substance into the focus of an international research effort. The episode’s lasting importance lies both in what researchers tried to learn and in how the compound unsettled familiar boundaries between medicine, psychology, and spiritual experience.

From Compound to Research Program

Hofmann took what the book describes as the world’s first LSD trip in 1943. The absence of an established script for interpreting the experience mattered: unlike later participants, he had not been primed by earlier accounts to expect a particular kind of revelation or disturbance. His uncertainty did not prevent him from seeing possible scientific value in LSD-25. Sandoz, the pharmaceutical company where he worked, responded by making the compound available under the brand name Delysid and inviting researchers to investigate what it might be useful for.

From 1949 to 1966, Sandoz’s policy was unusually generous. The company offered to supply researchers with as much LSD as they requested, at no charge; the definition of researcher extended to therapists willing to record their clinical observations. In effect, a pharmaceutical company distributed the research question across a dispersed community, hoping that investigators would discover a useful application. This was not a single coordinated experiment with one agreed protocol. It created conditions for varied clinical and psychological inquiries, and made the later body of research difficult to treat as a unified test of one hypothesis.

Experience, Expectation, and Interpretation

The studies that followed confronted a difficulty built into the experience itself: expectations could help shape what participants reported. Researchers and participants might approach LSD expecting spiritual insight, temporary insanity, access to the collective unconscious, cosmic consciousness, or a return to birth trauma. Such expectations could become self-fulfilling, making it hard to separate the compound’s effects from the ideas and instructions surrounding its use.

Aldous Huxley’s account of mescaline became an especially influential frame for later psychedelic experience. Published in 1954, The Doors of Perception gave prominence to Huxley’s interest in Eastern mysticism; from then on, that spiritual orientation helped shape the cultural understanding of LSD as well. Timothy Leary and his Harvard colleagues later amplified this approach in a manual based on the Tibetan Book of the Dead. The relationship ran in both directions: a scientist had given Huxley mescaline in the hope that a gifted writer’s descriptions would help researchers make sense of an experience they found difficult to interpret. The resulting history leaves interpretation entangled with observation: accounts of LSD both described experiences and helped furnish expectations for future ones.

That entanglement complicated efforts to establish LSD as a psychiatric treatment. Some researchers’ enthusiasm could contribute to favorable results while also intensifying skepticism among colleagues who had not taken the drug. Researchers also had to ask whether conventional controls could work when the participant’s expectations, the clinician’s expectations, and the surrounding environment could all influence the session. The compound did not arrive in a neutral clinical setting: the setting itself became part of the question under investigation.

Treatment and the Importance of Setting

The work of Humphry Osmond and Abram Hoffer with alcohol-dependent patients illustrates how clinical practice and interpretation developed alongside the drug’s distribution. Their volunteers’ experiences led them to reconsider a model that treated LSD chiefly as a temporary imitation of psychosis. Some reported effects that appeared more like transcendence or spiritual insight than insanity. Huxley’s own mescaline experience strengthened their doubts: what a psychiatrist might classify as depersonalization, hallucination, or mania might also be understood as mystical union, visionary experience, or ecstasy.

Osmond and Hoffer also learned that the environment of a session could strongly affect its character. They came to value an engaged, empathetic therapist, ideally one with personal experience of LSD, and suspected that some adverse reactions might be linked to the impersonal atmosphere of a white room and white-coated clinician. Although the language of set and setting became closely associated with later work at Harvard, these Saskatchewan researchers were already recognizing the importance of the participant’s psychological orientation and surroundings.

By the end of the 1950s, LSD was widely regarded in North America as a promising treatment for alcohol addiction, and the Saskatchewan provincial government helped make LSD therapy a standard treatment option for alcoholics in the province. The results nevertheless remained contested. In the early 1960s, Toronto’s Addiction Research Foundation attempted to reproduce the Saskatchewan work under tighter controls. Clinicians placed volunteers in neutral rooms, limited engagement during their sessions, and used questionnaires in an effort to isolate the drug’s effects. Some participants were restrained or blindfolded. The results did not match the Saskatchewan outcomes, and several volunteers had frightening experiences. The disagreement revealed a methodological tension rather than a simple verdict: critics could point to weaker results under rigorous controls, while supporters could argue that the stripped-down conditions had removed elements essential to the treatment.

Circulation, Networks, and Withdrawal

LSD’s movement through this period depended on people who carried both the compound and practical knowledge between research centers. By the late 1950s, Al Hubbard was visiting researchers across North America, assisting Osmond and Hoffer in Weyburn, meeting R. Gordon Wasson in Manhattan, and working with Betty Eisner, Sidney Cohen, and Oscar Janiger in Los Angeles. He shared treatment techniques as well as Sandoz LSD. In Vancouver, he persuaded Hollywood Hospital to dedicate a wing to alcohol treatment and established two other Canadian facilities. The resulting Hubbard-method treatment became a business, though Hubbard opposed profiting from LSD and gave away much of his fortune to advance the work.

The circulation was not confined to clinical programs. After a 66-microgram LSD experience, Myron Stolaroff began meeting with colleagues at Ampex to discuss spiritual questions and the possibility that LSD could help healthy people realize their potential. Hubbard later guided members of the group and trained them to guide others. Stolaroff tried to reshape Ampex into a psychedelic corporation, including workshops and sessions for executives, before leaving the company in 1961 to establish the International Foundation for Advanced Study with Willis Harman. The foundation obtained research permission from the FDA and received LSD and mescaline through Hubbard. These efforts show how access to the compound could support projects beyond conventional treatment, while also drawing new institutions and professional networks into the field.

The same circulation left unanswered questions. Hubbard connected distant research and treatment centers, but the book does not establish whether he also passed information to the CIA; people who knew him disagreed, and he criticized the agency’s uses of LSD. Sandoz’s policy itself came to an abrupt end in 1966, when controversy surrounding the experimental drug led the company to withdraw Delysid from circulation. The withdrawal marked a break in the research environment the company’s policy had helped create. The synthesis had made LSD-25 available as an object of investigation; its subsequent history showed that the drug’s meaning and apparent effects could not be separated easily from who administered it, what participants had been led to expect, and the conditions in which it was used.